Investigational drug · Phase 2
ABBV-916
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer's Disease (AD).
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "ABBV-916"
First trial start
2022
Aug 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABBV-916", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer's Disease (AD)
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABBV-916" as an intervention, largest first.
- A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's DiseasePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT05291234 · 106 participants · Start Aug 15, 2022 · Primary completion Nov 19, 2025
Drug: ABBV-916; Placebo · For: Alzheimer's Disease (AD)
Sites: Tucson, Arizona; Irvine, California; San Diego, California · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A randomized phase 1b/2 trial of ABBV-916 in adults with early Alzheimer's disease.
Lynch SY, Wang Y, Wang D, et al. · Alzheimers Dement 2026
- Safety, Tolerability, and Pharmacokinetics of Single Doses of ABBV-916, an Anti-Amyloid Antibody, in Healthy Participants.
Bachhav SS, Florian H, Boiser J, et al. · Clin Transl Sci 2026
- Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis.
Liao F, Calvo-Rodriguez M, Chhaya M, et al. · Acta Neuropathol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.